Next 10 |
Conference call to be on Wednesday, April 3, 2024, at 5 p.m. EDT Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc ...
2024-03-09 04:50:41 ET Summary Health Catalyst reported strong Q4 results, meeting guidance and showing growth in technology and professional services revenue. The drop in HCAT's share price presents a buying opportunity, as the company's growth initiatives, such as its TEMS offer...
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use Simulations Plus, Inc . (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling a...
Strategic investments in early-stage companies to drive innovation and collaboration Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today provided additi...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February. The Company will be presenting at Oppenheimer’s 34 th ...
2024-02-01 15:27:39 ET Summary Today, we circle back on Simulations Plus, Inc., a health information services company focused on drug discovery and development software. Analysts have reissued Buy ratings on the stock, but the high valuation and potential competition from generati...
New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industrie...
2024-01-25 08:00:18 ET Simulations Plus Inc. (SLP) declaring a stock dividend of $0.06 per share on Ex-Date : January 26, 2024. Shareholders on record as of January 29, 2024 are eligible for the dividend. The payment date is scheduled for February 05, 2024, and the declaration was o...
2024-01-11 13:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Conference call to be on Wednesday, April 3, 2024, at 5 p.m. EDT Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn O’Connor, chief executive officer, will be hosting a fireside chat at the KeyBanc ...
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use Simulations Plus, Inc . (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling a...